ZymoGenetics Company Description
ZymoGenetics has proteins on its plate. The firm culls genomics databases to indentify and develop protein-based drugs targeting a variety conditions, including autoimmune diseases and cancer. Its sole commercial product, RECOTHROM (rThrombin), controls bleeding during surgery. Unlike existing forms of thrombin, RECOTHROM is derived from recombinant proteins instead of animal or human blood which can trigger adverse reactions. The company's pipeline also includes cancer treatments Interleukin 21 and Atacicept. Novo Nordisk owned ZymoGenetics for a dozen years and still holds a 30% stake in the company.
View the Comprehensive Company Description for ZymoGenetics
The Company Description provides a historical perspective of ZymoGenetics's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of ZymoGenetics's evolution in the marketplace.
